Amrutanjan CARE Rating Assigned: CARE A/Stable Issuer Rating Reflects Strong Brand and Debt-Free Balance Sheet

What Happened ?

Amrutanjan informed the stock exchanges that CARE Ratings has assigned a CARE A; Stable issuer rating. According to CARE, the rating is supported by the company’s 133-year operating history, strong OTC pain relief brand, diversified product portfolio, extensive distribution network, debt-free balance sheet, and healthy liquidity position.

key details

Key Strengths Highlighted by CARE:

• Over 133 years of operating history.
• Strong consumer recall for the Amrutanjan Pain Balm brand.
• Diversified portfolio including Relief, Comfy, Enerlyte, Electro+, Fruitnik, and Smoothe.
• Extensive nationwide distribution network.
• Products available across general trade, chemists, organised retail, e-commerce, and quick commerce platforms.
• Presence in 1.11 million retail outlets through 1,656 distributors.
• Strong presence across southern and eastern India, contributing around 60% of FY26 revenue. 

Strong Financial Position:

• Debt-free capital structure.
• Net worth of ₹368.78 crore as of March 31, 2026.
• Cash and bank balances of ₹221.85 crore.
• Sanitary napkin manufacturing plant funded entirely through internal accruals.
• No material debt-funded investments planned, supporting a comfortable financial profile. 

Growth Initiatives:

• In-house sanitary napkin manufacturing commenced in June 2026.
• Expansion into personal care with the Smoothe razor brand.
• Production line upgraded to cGMP standards to support exports.
• Beverage portfolio aligned with revised ORS regulations.
• In-house manufacturing expected to improve profitability in women’s hygiene products. 

Key Rating Constraints:

• Modest scale relative to larger FMCG peers.
• Around 60% of revenue continues to come from the pain relief segment.
• Profitability remains vulnerable to menthol and petroleum-based raw material price volatility.
• Intense competition across the FMCG and healthcare sectors.
• Limited export contribution of around 2% of FY26 revenue. 

Risk Analysis

Summary:

• The assigned rating reflects Amrutanjan’s strong financial profile and established consumer brands. However, concentration in pain relief products, raw material price volatility, and competitive pressures remain key risks.

Key Risks:

• Dependence on the pain relief segment.
• Raw material cost volatility, particularly menthol and petroleum derivatives.
• Intense competition from established FMCG and healthcare companies.
• Profitability of newer business segments remains in the scale-up phase.

Worst Case:

• Sustained decline in operating income below ₹400 crore, deterioration in profitability, or significant debt-funded expansion could pressure the company’s credit profile. 

Risk Level: Low to Moderate

Company Commentary

Amrutanjan informed the exchanges that CARE Ratings has assigned a CARE A; Stable issuer rating. The company also stated that the detailed credit rating rationale has been made available on its website in accordance with the SEBI Listing Regulations.